25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Enanta Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Enanta together

I guess you are interested in Enanta Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Enanta Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Enanta Pharmaceuticals Inc

I send you an email if I find something interesting about Enanta Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Enanta (30 sec.)










1.2. What can you expect buying and holding a share of Enanta? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$7.03
Expected worth in 1 year
$2.83
How sure are you?
47.5%

+ What do you gain per year?

Total Gains per Share
$-4.20
Return On Investment
-40.5%

For what price can you sell your share?

Current Price per Share
$10.36
Expected price per share
$8.08 - $11.28
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Enanta (5 min.)




Live pricePrice per Share (EOD)
$10.36
Intrinsic Value Per Share
$-72.18 - $18.71
Total Value Per Share
$-65.15 - $25.73

2.2. Growth of Enanta (5 min.)




Is Enanta growing?

Current yearPrevious yearGrowGrow %
How rich?$148.9m$282.3m-$101.4m-56.1%

How much money is Enanta making?

Current yearPrevious yearGrowGrow %
Making money-$28.8m-$33m$4.1m14.5%
Net Profit Margin-160.7%-167.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Enanta (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#302 / 960

Most Revenue
#226 / 960

Most Profit
#762 / 960

Most Efficient
#530 / 960
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Enanta?

Welcome investor! Enanta's management wants to use your money to grow the business. In return you get a share of Enanta.

First you should know what it really means to hold a share of Enanta. And how you can make/lose money.

Speculation

The Price per Share of Enanta is $10.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enanta.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enanta, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.03. Based on the TTM, the Book Value Change Per Share is $-1.05 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enanta.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.07-10.3%-1.36-13.1%-1.56-15.0%-1.06-10.2%-0.27-2.6%
Usd Book Value Change Per Share-0.81-7.8%-1.05-10.1%-1.18-11.4%-0.71-6.8%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.81-7.8%-1.05-10.1%-1.18-11.4%-0.71-6.8%0.000.0%
Usd Price Per Share12.97-12.75-40.06-43.30-47.95-
Price to Earnings Ratio-3.03--2.40--6.88--7.16--2.25-
Price-to-Total Gains Ratio-15.98--12.40--38.89--31.72-14.14-
Price to Book Ratio1.85-1.55-2.95-2.55-3.13-
Price-to-Total Gains Ratio-15.98--12.40--38.89--31.72-14.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.36
Number of shares96
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.05-0.71
Usd Total Gains Per Share-1.05-0.71
Gains per Quarter (96 shares)-100.70-67.78
Gains per Year (96 shares)-402.80-271.10
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-403-4130-271-281
20-806-8160-542-552
30-1208-12190-813-823
40-1611-16220-1084-1094
50-2014-20250-1356-1365
60-2417-24280-1627-1636
70-2820-28310-1898-1907
80-3222-32340-2169-2178
90-3625-36370-2440-2449
100-4028-40400-2711-2720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%15.025.00.037.5%22.031.00.041.5%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%19.021.00.047.5%25.026.02.047.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.053.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%3.017.00.015.0%19.021.00.047.5%25.026.02.047.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Enanta Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.812-1.049+29%-1.182+46%-0.706-13%-0.005-99%
Book Value Per Share--7.0288.538-18%13.325-47%16.533-57%15.244-54%
Current Ratio--4.9226.084-19%9.448-48%12.387-60%16.441-70%
Debt To Asset Ratio--0.6270.577+9%0.243+158%0.211+196%0.134+369%
Debt To Equity Ratio--1.6781.383+21%0.404+315%0.410+310%0.234+616%
Dividend Per Share----0%-0%-0%-0%
Eps---1.069-1.361+27%-1.558+46%-1.059-1%-0.267-75%
Free Cash Flow Per Share---1.006-1.184+18%-1.253+25%-0.787-22%-0.117-88%
Free Cash Flow To Equity Per Share---1.320-1.425+8%1.119-218%-0.290-78%0.146-1003%
Gross Profit Margin--1.0261.007+2%1.000+3%1.001+2%1.001+3%
Intrinsic Value_10Y_max--18.705--------
Intrinsic Value_10Y_min---72.175--------
Intrinsic Value_1Y_max---0.129--------
Intrinsic Value_1Y_min---5.147--------
Intrinsic Value_3Y_max--1.139--------
Intrinsic Value_3Y_min---17.363--------
Intrinsic Value_5Y_max--4.248--------
Intrinsic Value_5Y_min---31.565--------
Market Cap219513896.000-25%274816142.000270207621.500+2%848762344.500-68%917455785.700-70%1015977478.550-73%
Net Profit Margin---1.261-1.607+27%-1.677+33%-1.147-9%-0.568-55%
Operating Margin---1.346-1.599+19%-1.704+27%-1.255-7%-0.636-53%
Operating Ratio--2.3462.738-14%2.721-14%2.272+3%2.071+13%
Pb Ratio1.474-25%1.8451.551+19%2.946-37%2.547-28%3.130-41%
Pe Ratio-2.422+20%-3.032-2.399-21%-6.880+127%-7.163+136%-2.254-26%
Price Per Share10.360-25%12.97012.753+2%40.058-68%43.300-70%47.949-73%
Price To Free Cash Flow Ratio-2.574+20%-3.223-2.697-16%-9.775+203%-9.000+179%34.068-109%
Price To Total Gains Ratio-12.763+20%-15.979-12.396-22%-38.887+143%-31.720+99%14.138-213%
Quick Ratio--7.99610.105-21%14.690-46%20.290-61%27.283-71%
Return On Assets---0.057-0.068+19%-0.087+53%-0.054-5%-0.009-84%
Return On Equity---0.152-0.161+6%-0.121-21%-0.082-46%-0.022-86%
Total Gains Per Share---0.812-1.049+29%-1.182+46%-0.706-13%-0.005-99%
Usd Book Value--148915000.000180912000.000-18%282341250.000-47%350310800.000-57%323007450.000-54%
Usd Book Value Change Per Share---0.812-1.049+29%-1.182+46%-0.706-13%-0.005-99%
Usd Book Value Per Share--7.0288.538-18%13.325-47%16.533-57%15.244-54%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.069-1.361+27%-1.558+46%-1.059-1%-0.267-75%
Usd Free Cash Flow---21317000.000-25082750.000+18%-26553250.000+25%-16666700.000-22%-2480125.000-88%
Usd Free Cash Flow Per Share---1.006-1.184+18%-1.253+25%-0.787-22%-0.117-88%
Usd Free Cash Flow To Equity Per Share---1.320-1.425+8%1.119-218%-0.290-78%0.146-1003%
Usd Market Cap219513896.000-25%274816142.000270207621.500+2%848762344.500-68%917455785.700-70%1015977478.550-73%
Usd Price Per Share10.360-25%12.97012.753+2%40.058-68%43.300-70%47.949-73%
Usd Profit---22658000.000-28832250.000+27%-33014250.000+46%-22425550.000-1%-5650925.000-75%
Usd Revenue--17971000.00017990000.0000%20147250.000-11%24462600.000-27%30109000.000-40%
Usd Total Gains Per Share---0.812-1.049+29%-1.182+46%-0.706-13%-0.005-99%
 EOD+3 -5MRQTTM+23 -11YOY+18 -165Y+4 -3010Y+5 -29

3.3 Fundamental Score

Let's check the fundamental score of Enanta Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.422
Price to Book Ratio (EOD)Between0-11.474
Net Profit Margin (MRQ)Greater than0-1.261
Operating Margin (MRQ)Greater than0-1.346
Quick Ratio (MRQ)Greater than17.996
Current Ratio (MRQ)Greater than14.922
Debt to Asset Ratio (MRQ)Less than10.627
Debt to Equity Ratio (MRQ)Less than11.678
Return on Equity (MRQ)Greater than0.15-0.152
Return on Assets (MRQ)Greater than0.05-0.057
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Enanta Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.968
Ma 20Greater thanMa 5011.453
Ma 50Greater thanMa 10012.643
Ma 100Greater thanMa 20012.875
OpenGreater thanClose9.960
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-09-11 21:43:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Enanta earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Enanta to the Biotechnology industry mean.
  • A Net Profit Margin of -126.1% means that $-1.26 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enanta Pharmaceuticals Inc:

  • The MRQ is -126.1%. The company is making a huge loss. -2
  • The TTM is -160.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-126.1%TTM-160.7%+34.6%
TTM-160.7%YOY-167.7%+7.0%
TTM-160.7%5Y-114.7%-46.0%
5Y-114.7%10Y-56.8%-57.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-126.1%-125.0%-1.1%
TTM-160.7%-192.6%+31.9%
YOY-167.7%-208.8%+41.1%
5Y-114.7%-372.5%+257.8%
10Y-56.8%-473.0%+416.2%
4.3.1.2. Return on Assets

Shows how efficient Enanta is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Enanta to the Biotechnology industry mean.
  • -5.7% Return on Assets means that Enanta generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enanta Pharmaceuticals Inc:

  • The MRQ is -5.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.7%TTM-6.8%+1.1%
TTM-6.8%YOY-8.7%+1.9%
TTM-6.8%5Y-5.4%-1.4%
5Y-5.4%10Y-0.9%-4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.7%-11.1%+5.4%
TTM-6.8%-11.9%+5.1%
YOY-8.7%-11.4%+2.7%
5Y-5.4%-13.1%+7.7%
10Y-0.9%-14.9%+14.0%
4.3.1.3. Return on Equity

Shows how efficient Enanta is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Enanta to the Biotechnology industry mean.
  • -15.2% Return on Equity means Enanta generated $-0.15 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enanta Pharmaceuticals Inc:

  • The MRQ is -15.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.2%TTM-16.1%+0.9%
TTM-16.1%YOY-12.1%-4.0%
TTM-16.1%5Y-8.2%-7.9%
5Y-8.2%10Y-2.2%-6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.2%-14.2%-1.0%
TTM-16.1%-16.0%-0.1%
YOY-12.1%-13.8%+1.7%
5Y-8.2%-19.1%+10.9%
10Y-2.2%-19.7%+17.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Enanta Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Enanta is operating .

  • Measures how much profit Enanta makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Enanta to the Biotechnology industry mean.
  • An Operating Margin of -134.6% means the company generated $-1.35  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enanta Pharmaceuticals Inc:

  • The MRQ is -134.6%. The company is operating very inefficient. -2
  • The TTM is -159.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-134.6%TTM-159.9%+25.3%
TTM-159.9%YOY-170.4%+10.5%
TTM-159.9%5Y-125.5%-34.4%
5Y-125.5%10Y-63.6%-61.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-134.6%-276.1%+141.5%
TTM-159.9%-331.9%+172.0%
YOY-170.4%-233.3%+62.9%
5Y-125.5%-388.9%+263.4%
10Y-63.6%-498.7%+435.1%
4.3.2.2. Operating Ratio

Measures how efficient Enanta is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.35 means that the operating costs are $2.35 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 2.346. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.738. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.346TTM2.738-0.392
TTM2.738YOY2.721+0.017
TTM2.7385Y2.272+0.466
5Y2.27210Y2.071+0.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3462.759-0.413
TTM2.7383.134-0.396
YOY2.7213.379-0.658
5Y2.2725.124-2.852
10Y2.0716.571-4.500
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Enanta Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Enanta is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.92 means the company has $4.92 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 4.922. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.084. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.922TTM6.084-1.163
TTM6.084YOY9.448-3.363
TTM6.0845Y12.387-6.303
5Y12.38710Y16.441-4.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9223.817+1.105
TTM6.0844.024+2.060
YOY9.4484.730+4.718
5Y12.3876.035+6.352
10Y16.4416.356+10.085
4.4.3.2. Quick Ratio

Measures if Enanta is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Enanta to the Biotechnology industry mean.
  • A Quick Ratio of 8.00 means the company can pay off $8.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 7.996. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.105. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.996TTM10.105-2.108
TTM10.105YOY14.690-4.585
TTM10.1055Y20.290-10.185
5Y20.29010Y27.283-6.993
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.9963.346+4.650
TTM10.1053.571+6.534
YOY14.6904.719+9.971
5Y20.2905.931+14.359
10Y27.2836.524+20.759
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Enanta Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Enanta assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Enanta to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.63 means that Enanta assets are financed with 62.7% credit (debt) and the remaining percentage (100% - 62.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 0.627. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.577. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.627TTM0.577+0.050
TTM0.577YOY0.243+0.334
TTM0.5775Y0.211+0.366
5Y0.21110Y0.134+0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6270.341+0.286
TTM0.5770.343+0.234
YOY0.2430.309-0.066
5Y0.2110.364-0.153
10Y0.1340.383-0.249
4.5.4.2. Debt to Equity Ratio

Measures if Enanta is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Enanta to the Biotechnology industry mean.
  • A Debt to Equity ratio of 167.8% means that company has $1.68 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 1.678. The company is just able to pay all its debts with equity.
  • The TTM is 1.383. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.678TTM1.383+0.295
TTM1.383YOY0.404+0.979
TTM1.3835Y0.410+0.974
5Y0.41010Y0.234+0.175
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6780.393+1.285
TTM1.3830.437+0.946
YOY0.4040.372+0.032
5Y0.4100.443-0.033
10Y0.2340.488-0.254
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Enanta generates.

  • Above 15 is considered overpriced but always compare Enanta to the Biotechnology industry mean.
  • A PE ratio of -3.03 means the investor is paying $-3.03 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enanta Pharmaceuticals Inc:

  • The EOD is -2.422. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.032. Based on the earnings, the company is expensive. -2
  • The TTM is -2.399. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.422MRQ-3.032+0.610
MRQ-3.032TTM-2.399-0.633
TTM-2.399YOY-6.880+4.481
TTM-2.3995Y-7.163+4.764
5Y-7.16310Y-2.254-4.909
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.422-2.343-0.079
MRQ-3.032-2.383-0.649
TTM-2.399-2.926+0.527
YOY-6.880-3.429-3.451
5Y-7.163-5.973-1.190
10Y-2.254-6.253+3.999
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enanta Pharmaceuticals Inc:

  • The EOD is -2.574. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.223. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.697. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.574MRQ-3.223+0.649
MRQ-3.223TTM-2.697-0.526
TTM-2.697YOY-9.775+7.078
TTM-2.6975Y-9.000+6.303
5Y-9.00010Y34.068-43.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.574-3.032+0.458
MRQ-3.223-3.177-0.046
TTM-2.697-3.497+0.800
YOY-9.775-4.592-5.183
5Y-9.000-8.156-0.844
10Y34.068-8.700+42.768
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Enanta is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.85 means the investor is paying $1.85 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Enanta Pharmaceuticals Inc:

  • The EOD is 1.474. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.845. Based on the equity, the company is underpriced. +1
  • The TTM is 1.551. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.474MRQ1.845-0.371
MRQ1.845TTM1.551+0.295
TTM1.551YOY2.946-1.395
TTM1.5515Y2.547-0.996
5Y2.54710Y3.130-0.582
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4741.901-0.427
MRQ1.8451.972-0.127
TTM1.5512.199-0.648
YOY2.9462.359+0.587
5Y2.5473.563-1.016
10Y3.1304.192-1.062
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Enanta Pharmaceuticals Inc.

4.8.1. Institutions holding Enanta Pharmaceuticals Inc

Institutions are holding 104.538% of the shares of Enanta Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Farallon Capital Management, L.L.C.9.88740.1282209500000
2024-03-31Morgan Stanley - Brokerage Accounts9.65210.0029204514587208774.343
2024-06-30Vanguard Group Inc9.12940.0005193439063120.3274
2024-06-30BlackRock Inc8.71940.0005184751984640.4602
2024-06-30Krensavage Asset Management, LLC5.90577.4518125133812675211.271
2024-06-30Armistice Capital, LLC5.17260.17891096000-140000-11.3269
2024-06-30Caligan Partners LP4.92193.1604104288918481921.5389
2024-06-30Marshall Wace Asset Management Ltd4.38140.0161928363-22699-2.3867
2024-03-31Acadian Asset Management LLC4.030.0519853896109521.2993
2024-06-30Northern Trust Corp3.98850.0019845116-88240-9.4541
2024-06-30Soleus Capital Management, L.P.3.77350.914579954621900037.7231
2024-06-30Millennium Management LLC3.22410.0041683143-23105-3.2715
2024-06-30Bank of America Corp2.81240.00075959137954715.4052
2024-06-30D. E. Shaw & Co LP2.52110.0065534181-36065-6.3245
2024-06-30Renaissance Technologies Corp2.41120.0112510900-15200-2.8892
2024-06-30BOOTHBAY FUND MANAGEMENT, LLC2.28080.14854832769467624.3634
2024-06-30Geode Capital Management, LLC2.18410.0005462776207044.6834
2024-06-30Assenagon Asset Management SA2.01320.0123426561-157097-26.9159
2024-06-30State Street Corp1.99550.0002422828-1137-0.2682
2024-06-30TANG CAPITAL MANAGEMENT LLC1.41590.396330000000
Total 90.420212.487919158780+1139770+5.9%

4.9.2. Funds holding Enanta Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-07-31Vanguard Total Stock Mkt Idx Inv2.97140.000662959700
2024-08-30iShares Russell 2000 ETF2.57350.009954529534440.6356
2024-07-31Vanguard Institutional Extnd Mkt Idx Tr1.32910.003828161100
2024-06-30Vanguard Strategic Small-Cap Equity Inv1.27750.223527067593763.5882
2024-06-30Vanguard VIF Small Co Gr1.19580.221125336500
2024-06-30Fidelity Small Cap Index0.98450.010120859668843.4128
2024-05-31UBS (Lux) EF Biotech (USD) P-acc0.8930.4921189224-2296-1.1988
2024-08-30iShares Russell 2000 Value ETF0.8820.0192186879-625-0.3333
2024-06-30Vanguard Strategic Equity Inv0.8530.028318074100
2024-07-31Columbia Small Cap Value I A0.65860.13371395481395480
2024-07-31State St Russell Sm/Mid Cp® Indx NL Cl C0.62490.004313240100
2024-06-30Vanguard Explorer Inv0.56250.007111919100
2024-07-31Fidelity Extended Market Index0.53950.004111430617941.5945
2024-07-31BlackRock Advantage Small Cap Core Instl0.49480.040910483700
2024-08-31Schwab US Small-Cap ETF™0.45420.00699624600
2024-07-31JPMorgan Small Cap Value I0.45110.10139557866420227.7934
2024-07-31Vanguard Russell 2000 ETF0.37250.01077893041485.5468
2024-06-30Acadian Global Small-Cap Equity CIT Cl A0.34090.27272228-15230-17.4141
2024-07-31State St Russell Sm Cap® Indx SL Cl I0.33220.017038600
2024-07-31Vanguard Health Care ETF0.31550.004766860-352-0.5237
Total 18.10651.60433836494+213111+5.6%

5.3. Insider Transactions

Insiders are holding 6.09% of the shares of Enanta Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-07-15Scott T RottinghausSELL537517.08
2024-07-11Scott T RottinghausSELL429915.07
2024-06-17Tara Lynn KiefferSELL726612.33
2023-12-13Terry VanceSELL152959.12
2023-12-05Brendan LuuSELL21259.63
2023-12-05Jay R LulySELL72309.63
2023-12-05Paul J MellettSELL24129.63
2023-12-05Scott T RottinghausSELL5349.63
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets398,821
Total Liabilities249,906
Total Stockholder Equity148,915
 As reported
Total Liabilities 249,906
Total Stockholder Equity+ 148,915
Total Assets = 398,821

Assets

Total Assets398,821
Total Current Assets286,584
Long-term Assets112,237
Total Current Assets
Cash And Cash Equivalents 36,383
Short-term Investments 194,310
Net Receivables 40,631
Other Current Assets 15,260
Total Current Assets  (as reported)286,584
Total Current Assets  (calculated)286,584
+/-0
Long-term Assets
Property Plant Equipment 66,262
Long Term Investments 42,510
Long-term Assets Other 105
Long-term Assets  (as reported)112,237
Long-term Assets  (calculated)108,877
+/- 3,360

Liabilities & Shareholders' Equity

Total Current Liabilities58,231
Long-term Liabilities191,675
Total Stockholder Equity148,915
Total Current Liabilities
Short-term Debt 34,726
Accounts payable 10,675
Other Current Liabilities 12,830
Total Current Liabilities  (as reported)58,231
Total Current Liabilities  (calculated)58,231
+/-0
Long-term Liabilities
Capital Lease Obligations 50,567
Long-term Liabilities Other 142,116
Long-term Liabilities  (as reported)191,675
Long-term Liabilities  (calculated)192,683
+/- 1,008
Total Stockholder Equity
Common Stock212
Retained Earnings -294,217
Other Stockholders Equity 442,150
Total Stockholder Equity (as reported)148,915
Total Stockholder Equity (calculated)148,145
+/- 770
Other
Capital Stock212
Cash and Short Term Investments 230,693
Common Stock Shares Outstanding 21,180
Liabilities and Stockholders Equity 398,821
Net Debt 189,791
Net Invested Capital 148,915
Net Working Capital 228,353
Property Plant and Equipment Gross 91,474
Short Long Term Debt Total 226,174



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302010-09-30
> Total Assets 
2,412
26,096
0
0
54,326
52,162
72,483
125,627
119,671
116,973
110,158
108,346
159,514
155,415
215,427
245,884
237,774
246,013
278,379
281,595
281,934
281,277
278,379
278,958
275,837
326,637
340,719
354,654
379,085
414,227
454,216
461,578
473,484
489,829
510,974
513,501
511,704
486,132
481,012
467,767
450,436
438,791
440,594
406,818
385,214
375,410
347,534
326,445
495,169
462,275
428,499
413,557
398,821
398,821413,557428,499462,275495,169326,445347,534375,410385,214406,818440,594438,791450,436467,767481,012486,132511,704513,501510,974489,829473,484461,578454,216414,227379,085354,654340,719326,637275,837278,958278,379281,277281,934281,595278,379246,013237,774245,884215,427155,415159,514108,346110,158116,973119,671125,62772,48352,16254,3260026,0962,412
   > Total Current Assets 
0
25,099
0
0
50,781
47,308
60,951
111,664
97,866
104,713
94,378
99,349
111,678
107,975
185,096
177,784
172,640
170,641
209,021
242,665
241,790
232,156
224,065
190,591
206,115
237,819
247,626
305,677
339,893
380,389
423,310
423,840
451,262
401,848
440,508
402,709
413,381
436,837
445,942
428,219
321,155
319,021
326,957
341,869
313,035
311,713
283,704
271,137
448,465
422,791
390,303
351,029
286,584
286,584351,029390,303422,791448,465271,137283,704311,713313,035341,869326,957319,021321,155428,219445,942436,837413,381402,709440,508401,848451,262423,840423,310380,389339,893305,677247,626237,819206,115190,591224,065232,156241,790242,665209,021170,641172,640177,784185,096107,975111,67899,34994,378104,71397,866111,66460,95147,30850,7810025,0990
       Cash And Cash Equivalents 
466
6,837
0
0
3,961
10,511
20,735
74,464
18,878
8,859
4,426
18,101
26,374
30,699
34,130
25,751
19,844
21,726
46,233
56,360
24,789
16,577
20,618
19,211
22,263
65,675
68,053
66,926
42,477
63,902
74,365
106,030
94,206
51,230
27,558
74,338
99,855
87,131
55,095
77,126
4,601
57,206
99,068
40,989
28,367
43,994
42,223
73,178
95,177
85,388
39,933
63,542
36,383
36,38363,54239,93385,38895,17773,17842,22343,99428,36740,98999,06857,2064,60177,12655,09587,13199,85574,33827,55851,23094,206106,03074,36563,90242,47766,92668,05365,67522,26319,21120,61816,57724,78956,36046,23321,72619,84425,75134,13030,69926,37418,1014,4268,85918,87874,46420,73510,5113,961006,837466
       Short-term Investments 
0
16,492
0
0
42,803
33,251
24,750
34,647
75,668
92,621
87,469
76,669
69,513
60,065
69,892
139,721
134,442
123,479
133,786
164,062
193,676
193,507
188,740
156,362
169,752
157,994
152,389
189,797
230,750
244,828
271,423
264,127
295,042
284,006
346,227
280,917
270,145
299,518
331,101
298,821
252,223
186,796
159,984
239,338
224,921
205,238
172,247
136,906
291,408
284,522
297,218
236,768
194,310
194,310236,768297,218284,522291,408136,906172,247205,238224,921239,338159,984186,796252,223298,821331,101299,518270,145280,917346,227284,006295,042264,127271,423244,828230,750189,797152,389157,994169,752156,362188,740193,507193,676164,062133,786123,479134,442139,72169,89260,06569,51376,66987,46992,62175,66834,64724,75033,25142,8030016,4920
       Net Receivables 
0
261
0
0
3,489
2,942
14,876
1,437
1,857
1,592
1,208
2,602
2,658
4,494
78,508
8,631
13,100
15,722
18,878
13,004
13,978
12,841
10,417
8,959
7,511
10,614
23,109
44,049
57,262
67,205
69,886
39,631
44,367
51,313
52,570
27,619
18,653
23,492
31,743
20,132
52,194
60,831
56,399
47,464
48,207
49,036
51,288
46,569
44,809
39,618
39,907
39,787
40,631
40,63139,78739,90739,61844,80946,56951,28849,03648,20747,46456,39960,83152,19420,13231,74323,49218,65327,61952,57051,31344,36739,63169,88667,20557,26244,04923,10910,6147,5118,95910,41712,84113,97813,00418,87815,72213,1008,63178,5084,4942,6582,6021,2081,5921,8571,43714,8762,9423,489002610
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
997
0
0
3,545
4,854
11,532
13,963
21,805
12,260
15,780
8,997
47,836
47,440
30,331
68,100
65,134
75,372
69,358
38,930
40,144
49,121
54,314
88,367
69,722
88,818
93,093
48,977
39,192
33,838
30,906
37,738
22,222
87,981
70,466
110,792
98,323
49,295
35,070
39,548
129,281
119,770
113,637
64,949
72,179
63,697
63,830
55,308
46,704
39,484
38,196
62,528
112,237
112,23762,52838,19639,48446,70455,30863,83063,69772,17964,949113,637119,770129,28139,54835,07049,29598,323110,79270,46687,98122,22237,73830,90633,83839,19248,97793,09388,81869,72288,36754,31449,12140,14438,93069,35875,37265,13468,10030,33147,44047,8368,99715,78012,26021,80513,96311,5324,8543,545009970
       Property Plant Equipment 
590
534
0
0
539
611
583
876
1,152
1,121
1,077
1,377
1,551
1,803
1,922
2,295
2,582
5,886
7,872
7,691
7,499
8,004
8,306
8,526
8,070
8,049
7,870
8,616
8,383
8,374
9,493
11,476
11,373
10,927
18,169
17,575
16,930
15,616
15,563
14,010
12,530
10,654
24,269
22,031
28,081
29,748
32,222
35,604
35,982
34,713
33,463
58,373
66,262
66,26258,37333,46334,71335,98235,60432,22229,74828,08122,03124,26910,65412,53014,01015,56315,61616,93017,57518,16910,92711,37311,4769,4938,3748,3838,6167,8708,0498,0708,5268,3068,0047,4997,6917,8725,8862,5822,2951,9221,8031,5511,3771,0771,1211,15287658361153900534590
       Long Term Investments 
0
0
0
0
0
0
0
12,629
20,217
10,703
14,267
7,184
41,700
41,003
23,568
61,330
57,657
64,238
56,618
25,224
26,194
32,119
35,037
65,330
43,321
70,038
77,047
32,186
22,272
16,389
11,465
16,510
0
65,013
40,941
80,099
65,404
32,634
18,462
24,493
115,706
108,416
88,668
42,218
39,427
29,285
26,939
15,040
5,924
0
0
0
42,510
42,5100005,92415,04026,93929,28539,42742,21888,668108,416115,70624,49318,46232,63465,40480,09940,94165,013016,51011,46516,38922,27232,18677,04770,03843,32165,33035,03732,11926,19425,22456,61864,23857,65761,33023,56841,00341,7007,18414,26710,70320,21712,6290000000
       Long-term Assets Other 
0
463
0
0
1,344
2,587
3,520
458
436
436
436
436
436
436
436
608
608
608
608
608
608
608
608
608
608
608
608
608
608
700
700
700
700
700
700
700
700
700
700
700
700
700
700
700
4,671
4,664
4,669
4,664
4,798
4,771
765
187
105
1051877654,7714,7984,6644,6694,6644,6717007007007007007007007007007007007007007007006086086086086086086086086086086086086086084364364364364364364364583,5202,5871,344004630
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
4,149
4,198
4,405
3,867
4,287
4,640
4,260
5,407
5,843
8,390
10,363
13,903
17,723
10,123
7,568
7,567
7,929
8,375
9,248
9,052
10,149
0
10,656
12,418
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000012,41810,656010,1499,0529,2488,3757,9297,5677,56810,12317,72313,90310,3638,3905,8435,4074,2604,6404,2873,8674,4054,1984,149000000000000
> Total Liabilities 
0
158,057
0
0
164,578
8,233
6,265
7,252
5,260
6,505
4,578
6,631
6,561
6,761
21,714
21,669
9,492
9,856
14,100
15,180
12,927
11,341
10,211
12,947
14,971
24,961
23,140
21,252
18,184
20,548
27,381
25,368
25,387
27,337
28,687
27,510
31,147
30,552
29,017
31,735
32,586
39,362
56,210
48,235
47,191
54,076
46,697
57,070
257,350
245,540
236,615
247,443
249,906
249,906247,443236,615245,540257,35057,07046,69754,07647,19148,23556,21039,36232,58631,73529,01730,55231,14727,51028,68727,33725,38725,36827,38120,54818,18421,25223,14024,96114,97112,94710,21111,34112,92715,18014,1009,8569,49221,66921,7146,7616,5616,6314,5786,5055,2607,2526,2658,233164,57800158,0570
   > Total Current Liabilities 
3,999
2,149
0
0
3,922
5,734
3,772
4,951
2,941
4,526
2,568
4,419
4,268
4,746
19,866
19,790
7,312
6,704
10,872
11,988
9,569
7,889
6,431
9,154
11,122
20,982
19,222
17,117
14,029
16,025
22,632
20,491
20,501
22,609
19,139
19,516
23,914
24,157
23,044
26,618
28,624
36,172
37,890
30,738
23,035
29,827
23,001
32,166
68,189
62,787
62,407
54,608
58,231
58,23154,60862,40762,78768,18932,16623,00129,82723,03530,73837,89036,17228,62426,61823,04424,15723,91419,51619,13922,60920,50120,49122,63216,02514,02917,11719,22220,98211,1229,1546,4317,8899,56911,98810,8726,7047,31219,79019,8664,7464,2684,4192,5684,5262,9414,9513,7725,7343,922002,1493,999
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
202
0
0
0
69
69
52
71
73
75
75
75
79
1,886
1,865
1,843
0
0
0
0
0
3,132
3,764
4,264
4,261
5,197
5,175
5,034
4,203
3,469
3,013
2,599
2,891
3,486
4,923
5,368
5,275
4,966
37,252
34,726
34,72637,2524,9665,2755,3684,9233,4862,8912,5993,0133,4694,2035,0345,1755,1974,2614,2643,7643,132000001,8431,8651,8867975757573715269690002020000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
202
0
0
0
761
0
0
0
690
0
0
641
1,220
1,886
1,865
1,843
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001,8431,8651,8861,220641006900007610002020000000000000
       Accounts payable 
508
566
0
0
833
1,851
1,774
2,371
918
1,481
840
2,041
1,284
1,874
567
2,343
1,614
1,543
2,767
2,572
2,044
3,377
1,952
4,056
5,488
3,714
3,268
4,696
4,902
4,745
5,622
8,884
6,504
6,689
6,596
5,945
6,074
5,737
6,305
5,699
5,895
9,540
7,841
5,985
1,245
6,000
4,352
11,761
7,932
4,097
9,326
6,726
10,675
10,6756,7269,3264,0977,93211,7614,3526,0001,2455,9857,8419,5405,8955,6996,3055,7376,0745,9456,5966,6896,5048,8845,6224,7454,9024,6963,2683,7145,4884,0561,9523,3772,0442,5722,7671,5431,6142,3435671,8741,2842,0418401,4819182,3711,7741,85183300566508
       Other Current Liabilities 
3,491
1,583
0
0
3,089
3,866
1,857
2,465
2,023
3,035
1,723
2,327
2,984
2,872
19,299
17,447
5,698
3,893
3,096
2,580
4,512
4,439
4,404
5,023
5,559
7,891
15,954
12,421
9,127
11,280
17,010
11,607
13,997
15,920
9,411
9,807
13,576
14,159
11,542
15,744
17,695
22,429
26,580
21,740
19,191
20,936
15,163
15,482
36,693
35,076
36,512
10,630
12,830
12,83010,63036,51235,07636,69315,48215,16320,93619,19121,74026,58022,42917,69515,74411,54214,15913,5769,8079,41115,92013,99711,60717,01011,2809,12712,42115,9547,8915,5595,0234,4044,4394,5122,5803,0963,8935,69817,44719,2992,8722,9842,3271,7233,0352,0232,4651,8573,8663,089001,5833,491
   > Long-term Liabilities 
0
155,908
0
0
160,656
2,499
2,493
2,301
2,319
1,979
2,010
2,212
2,293
2,015
1,848
1,879
2,180
3,152
3,228
3,192
3,358
3,452
3,780
3,793
3,849
3,979
3,918
4,135
4,155
4,523
4,749
4,877
4,886
4,728
9,548
7,994
7,233
6,395
5,973
5,117
3,962
3,190
18,320
17,497
24,156
24,249
23,696
24,904
189,161
182,753
174,208
192,835
191,675
191,675192,835174,208182,753189,16124,90423,69624,24924,15617,49718,3203,1903,9625,1175,9736,3957,2337,9949,5484,7284,8864,8774,7494,5234,1554,1353,9183,9793,8493,7933,7803,4523,3583,1923,2283,1522,1801,8791,8482,0152,2932,2122,0101,9792,3192,3012,4932,499160,65600155,9080
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,899
1,877
1,852
1,828
1,628
1,628
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000001,6281,6281,8281,8521,8771,899000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
-202
0
0
0
-69
-69
-52
-71
-73
-75
-75
-75
-79
-1,886
-1,865
-1,843
0
0
249
224
200
5,987
5,330
4,547
3,838
3,520
2,644
1,637
1,126
15,958
15,115
22,209
22,372
21,859
23,073
22,333
21,238
20,524
9,741
15,841
15,8419,74120,52421,23822,33323,07321,85922,37222,20915,11515,9581,1261,6372,6443,5203,8384,5475,3305,98720022424900-1,843-1,865-1,886-79-75-75-75-73-71-52-69-69000-2020000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
4,149
4,198
4,405
3,867
4,287
4,640
4,260
5,407
5,843
8,390
10,363
13,903
17,723
10,123
7,568
7,567
7,929
8,375
9,248
9,052
10,149
0
10,656
12,418
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000012,41810,656010,1499,0529,2488,3757,9297,5677,56810,12317,72313,90310,3638,3905,8435,4074,2604,6404,2873,8674,4054,1984,149000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
206
213
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000021320600000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
534
535
359
373
389
405
431
421
1,879
2,180
3,152
3,228
3,192
3,358
3,452
3,780
3,793
3,849
3,979
3,918
4,135
4,155
4,523
4,749
4,877
1,865
1,746
9,548
7,994
7,233
6,395
5,973
5,117
846
558
856
17,497
87
454
23,696
24,904
165,405
160,092
152,261
148,000
142,116
142,116148,000152,261160,092165,40524,90423,6964548717,4978565588465,1175,9736,3957,2337,9949,5481,7461,8654,8774,7494,5234,1554,1353,9183,9793,8493,7933,7803,4523,3583,1923,2283,1522,1801,8794214314053893733595355340000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
1,767
1,784
1,620
1,637
1,617
1,675
1,584
1,427
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000001,4271,5841,6751,6171,6371,6201,7841,7670000000
> Total Stockholder Equity
0
-131,961
0
0
-110,252
43,929
66,218
118,375
114,411
110,468
105,580
101,715
152,953
148,654
193,713
224,215
228,282
236,157
264,279
266,415
269,007
269,936
268,168
266,011
260,866
301,676
317,579
333,402
360,901
393,679
426,835
436,210
448,097
462,492
482,287
485,991
480,557
455,580
451,995
436,032
417,850
399,429
384,384
358,583
338,023
321,334
300,837
269,375
237,819
216,735
191,884
166,114
148,915
148,915166,114191,884216,735237,819269,375300,837321,334338,023358,583384,384399,429417,850436,032451,995455,580480,557485,991482,287462,492448,097436,210426,835393,679360,901333,402317,579301,676260,866266,011268,168269,936269,007266,415264,279236,157228,282224,215193,713148,654152,953101,715105,580110,468114,411118,37566,21843,929-110,25200-131,9610
   Retained Earnings 
0
-132,004
0
0
-110,285
-115,374
-94,354
-98,869
-103,007
-107,450
-112,820
-118,023
-67,970
-73,012
-31,003
-2,250
168
5,980
32,169
30,524
29,448
27,646
22,666
17,274
8,848
45,356
57,094
69,649
89,937
117,357
143,368
147,513
154,549
163,740
177,183
171,178
156,913
127,572
119,244
97,199
73,175
48,576
18,461
-15,131
-46,831
-73,179
-102,165
-139,823
-178,888
-206,995
-240,402
-271,559
-294,217
-294,217-271,559-240,402-206,995-178,888-139,823-102,165-73,179-46,831-15,13118,46148,57673,17597,199119,244127,572156,913171,178177,183163,740154,549147,513143,368117,35789,93769,64957,09445,3568,84817,27422,66627,64629,44830,52432,1695,980168-2,250-31,003-73,012-67,970-118,023-112,820-107,450-103,007-98,869-94,354-115,374-110,28500-132,0040
   Accumulated Other Comprehensive Income 
0
-1
0
0
-15
10
-4
-7
-94
-2
32
61
-4
-100
-92
-17
-74
33
-189
201
117
19
-85
-108
-137
-112
-458
-794
-595
-398
-257
-12
163
146
234
608
1,458
844
405
55
-264
-382
-1,006
-3,037
-3,620
-3,724
-2,675
-1,815
-1,504
-1,174
-534
-667
-653
-653-667-534-1,174-1,504-1,815-2,675-3,724-3,620-3,037-1,006-382-264554058441,458608234146163-12-257-398-595-794-458-112-137-108-8519117201-18933-74-17-92-100-46132-2-94-7-410-1500-10
   Capital Surplus 
0
0
0
0
0
0
0
217,073
217,334
217,741
218,188
219,492
220,741
221,580
224,622
226,295
228,001
229,957
232,111
235,500
239,252
242,081
245,397
248,654
251,964
256,241
260,752
264,354
271,365
276,526
283,530
288,512
293,188
298,409
304,672
314,005
321,985
326,963
332,145
338,576
344,737
351,033
366,724
376,545
388,267
398,029
405,468
410,803
0
0
0
0
0
00000410,803405,468398,029388,267376,545366,724351,033344,737338,576332,145326,963321,985314,005304,672298,409293,188288,512283,530276,526271,365264,354260,752256,241251,964248,654245,397242,081239,252235,500232,111229,957228,001226,295224,622221,580220,741219,492218,188217,741217,334217,0730000000
   Treasury Stock000000000000000000000000000000000000-2-2-2-2-2-2-2-2-2-2-2-2000-2-3



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-09-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue79,204
Cost of Revenue-2,371
Gross Profit76,83376,833
 
Operating Income (+$)
Gross Profit76,833
Operating Expense-216,411
Operating Income-137,207-139,578
 
Operating Expense (+$)
Research Development163,524
Selling General Administrative52,887
Selling And Marketing Expenses0
Operating Expense216,411216,411
 
Net Interest Income (+$)
Interest Income11,360
Interest Expense-5,148
Other Finance Cost-0
Net Interest Income6,212
 
Pretax Income (+$)
Operating Income-137,207
Net Interest Income6,212
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-130,995-143,419
EBIT - interestExpense = -130,995
-130,995
-128,668
Interest Expense5,148
Earnings Before Interest and Taxes (EBIT)-125,847-125,847
Earnings Before Interest and Taxes (EBITDA)-123,476
 
After tax Income (+$)
Income Before Tax-130,995
Tax Provision-2,821
Net Income From Continuing Ops-133,816-133,816
Net Income-133,816
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses216,411
Total Other Income/Expenses Net6,212-6,212
 

Technical Analysis of Enanta
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enanta. The general trend of Enanta is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enanta's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enanta Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.74 < 11.01 < 11.28.

The bearish price targets are: 8.51 > 8.08.

Tweet this
Enanta Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enanta Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enanta Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enanta Pharmaceuticals Inc. The current macd is -0.66454453.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Enanta price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Enanta. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Enanta price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Enanta Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEnanta Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enanta Pharmaceuticals Inc. The current adx is 36.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Enanta shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Enanta Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enanta Pharmaceuticals Inc. The current sar is 11.14.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Enanta Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enanta Pharmaceuticals Inc. The current rsi is 24.97. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Enanta Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEnanta Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enanta Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Enanta price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Enanta Pharmaceuticals Inc Daily Stochastic Oscillator ChartEnanta Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enanta Pharmaceuticals Inc. The current cci is -168.20970913.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Enanta Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEnanta Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enanta Pharmaceuticals Inc. The current cmo is -67.25917027.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Enanta Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEnanta Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enanta Pharmaceuticals Inc. The current willr is -96.72447013.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Enanta Pharmaceuticals Inc Daily Williams %R ChartEnanta Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enanta Pharmaceuticals Inc. The current atr is 0.54206459.

Enanta Pharmaceuticals Inc Daily Average True Range (ATR) ChartEnanta Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enanta Pharmaceuticals Inc. The current obv is -18,592,857.

Enanta Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEnanta Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enanta Pharmaceuticals Inc. The current mfi is 12.58.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Enanta Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEnanta Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enanta Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-05-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-07-18ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Enanta Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enanta Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.968
Ma 20Greater thanMa 5011.453
Ma 50Greater thanMa 10012.643
Ma 100Greater thanMa 20012.875
OpenGreater thanClose9.960
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Enanta with someone you think should read this too:
  • Are you bullish or bearish on Enanta? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enanta? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enanta Pharmaceuticals Inc

I send you an email if I find something interesting about Enanta Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Enanta Pharmaceuticals Inc.

Receive notifications about Enanta Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.